CIP2A (Cancerous Inhibitor of Protein Phosphatase 2A) is a human oncoprotein that promotes cell proliferation and tumorigenesis by inhibiting the tumor-suppressive activity of protein phosphatase 2A (PP2A), a critical regulator of multiple signaling pathways. First identified in 2007. CIP2A is overexpressed in various cancers, including breast, lung, gastric, and hepatocellular carcinomas, and is associated with poor prognosis, metastasis, and therapy resistance. Its oncogenic role involves stabilizing oncoproteins like c-Myc by blocking PP2A-mediated dephosphorylation, thereby enhancing cell cycle progression and survival.
CIP2A antibodies are essential tools for detecting and quantifying CIP2A expression in research and diagnostic contexts. These antibodies enable techniques like Western blotting, immunohistochemistry, and immunofluorescence to study CIP2A's localization, expression patterns, and interactions in cancer models. Studies using CIP2A antibodies have revealed its involvement in regulating apoptosis, epithelial-mesenchymal transition (EMT), and DNA damage response, making it a potential therapeutic target. Inhibiting CIP2A with small molecules or siRNA, often validated using these antibodies, has shown promise in sensitizing cancer cells to chemotherapy. As research advances, CIP2A antibodies remain crucial for elucidating its molecular mechanisms and exploring clinical applications in cancer diagnostics and targeted therapies.